Tovecimig-Based Doublet Boosts Response and PFS in Advanced Biliary Tract Cancer
(MedPage Today) -- Investigational tovecimig combined with paclitaxel significantly improved the response rate and progression-free survival (PFS) in patients with previously treated advanced or metastatic biliary tract cancer, according to the...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.